The Food and Drug Administration (FDA) published findings that reveal people with cancer who contracted COVID-19 face an increased rate of hospitalization and a 16-fold increased mortality risk. Using real-world data analysis, the FDA’s Oncology Center of Excellence examined the clinical experience of patients with cancer who contracted COVID-19 to better under the impact of the disease in this patient population.
The analysis also found that cancer patients with COVID-19 are also more likely to have other health conditions compared to patients without COVID-19. Additionally, researchers found evidence of health disparities among cancer patients with COVID-19.
This analysis was part of the agency’s COVID-19 Evidence Accelerator.